Metabolomics of beta-blockers
Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Final Year Project |
Language: | English |
Published: |
2010
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/39680 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-39680 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-396802023-03-03T15:33:17Z Metabolomics of beta-blockers Tan, Ian Yong Ming. Chen Wei Ning, William School of Chemical and Biomedical Engineering DRNTU::Engineering::Chemical engineering::Biotechnology Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer of Carvedilol exhibits different pharmacological activity, their effects at the cellular level are not well understood. In order to better understand how each enantiomer affects cells, the metabolite profiles of vascular smooth muscle cells (A7r5) were analysed after incubating with S- and R-Carvedilol separately using GC-MS technology. 27 metabolites were shown to be commonly expressed in all the samples and of the 27 metabolites, 8 metabolites were identified to be of particular interest. These metabolites are lactic acid, alanine, succinic acid, 5-oxoproline and proline, spermidine, threonine and aspartic acid. These metabolites were closely related to the clinical effects of Carvedilol and the differences in the levels of metabolites, as analysed by GC-MS, further supported the known differences in the pharmacological effects of the two enantiomers. The results will lead to a better understanding of the metabolic pathway of Carvedilol and subsequently facilitate the development of novel drug applications utilising the special properties of Carvedilol. Bachelor of Engineering (Chemical and Biomolecular Engineering) 2010-06-02T09:00:31Z 2010-06-02T09:00:31Z 2010 2010 Final Year Project (FYP) http://hdl.handle.net/10356/39680 en Nanyang Technological University 51 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
DRNTU::Engineering::Chemical engineering::Biotechnology |
spellingShingle |
DRNTU::Engineering::Chemical engineering::Biotechnology Tan, Ian Yong Ming. Metabolomics of beta-blockers |
description |
Carvedilol is a nonselective β-blocker with multiple properties, including antioxidant properties, α-adrenergic blocking effects and inhibitory effects on calcium channels. It has been used in the clinical treatment of hypertension and congestive heart failure. While it is known that each enantiomer of Carvedilol exhibits different pharmacological activity, their effects at the cellular level are not well understood. In order to better understand how each enantiomer affects cells, the metabolite profiles of vascular smooth muscle cells (A7r5) were analysed after incubating with S- and R-Carvedilol separately using GC-MS technology. 27 metabolites were shown to be commonly expressed in all the samples and of the 27 metabolites, 8 metabolites were identified to be of particular interest. These metabolites are lactic acid, alanine, succinic acid, 5-oxoproline and proline, spermidine, threonine and aspartic acid. These metabolites were closely related to the clinical effects of Carvedilol and the differences in the levels of metabolites, as analysed by GC-MS, further supported the known differences in the pharmacological effects of the two enantiomers. The results will lead to a better understanding of the metabolic pathway of Carvedilol and subsequently facilitate the development of novel drug applications utilising the special properties of Carvedilol. |
author2 |
Chen Wei Ning, William |
author_facet |
Chen Wei Ning, William Tan, Ian Yong Ming. |
format |
Final Year Project |
author |
Tan, Ian Yong Ming. |
author_sort |
Tan, Ian Yong Ming. |
title |
Metabolomics of beta-blockers |
title_short |
Metabolomics of beta-blockers |
title_full |
Metabolomics of beta-blockers |
title_fullStr |
Metabolomics of beta-blockers |
title_full_unstemmed |
Metabolomics of beta-blockers |
title_sort |
metabolomics of beta-blockers |
publishDate |
2010 |
url |
http://hdl.handle.net/10356/39680 |
_version_ |
1759853845429616640 |